Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06891040

Enrollment

118

Registered

2025-03-24

Start date

2025-04-28

Completion date

2025-11-04

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

A multicenter, randomized, double-blind, vehicle controlled phase II clinical study

Interventions

DRUGVC005 Placebo group

VC005 Placebo group with Local topical application

DRUGVC005 groups

VC005 group with Local topical application

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF); 2. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions; 3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria;

Exclusion criteria

1. Skin damage or abnormalities that may affect the evaluation of the administration site of the investigational drug; 2. Skin diseases that are contraindicated in research or affect the evaluation of drug administration sites, including but not limited to psoriasis, acne, and skin cancer; 3. Suffering from autoimmune diseases other than AD, such as inflammatory bowel disease and rheumatoid arthritis, and the researchers believe that this disease will be detrimental to the evaluation of this study; 4. Current history of or presence of lymphoproliferative disorders, or signs or symptoms suggesting possible lymphoproliferative disorders, including lymphadenopathy or splenomegaly; 5. Various malignant tumors, or any history of malignant tumors within the past 5 years prior to screening (excluding completely resected cervical carcinoma in situ, non metastatic squamous cell carcinoma, basal cell carcinoma, or papillary thyroid carcinoma);

Design outcomes

Primary

Measure	Time frame
Changes in EASI（Eczema area and severity index） from baseline	8 week

Countries

China

Contacts

PRINCIPAL_INVESTIGATORQian jin Lu

Chinese Academy of Medical Sciences Hospital of Skin Disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026